Chioato, A <br/><br/>
Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study.  [electronic resource] 

 -  Clinical and vaccine immunology : CVI  Oct 2012 
 - 1597-602 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1556-679X 
<br/><br/><label>Standard No.: </label>10.1128/CVI.00386-12  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Antibodies, Bacterial--blood<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>Antibodies, Viral--blood<br/>Female<br/>Humans<br/>Influenza Vaccines--immunology<br/>Influenza, Human--immunology<br/>Interleukin-17--antagonists & inhibitors<br/>Male<br/>Meningococcal Infections--immunology<br/>Meningococcal Vaccines--immunology<br/>Middle Aged<br/>Neisseria meningitidis--immunology<br/>Orthomyxoviridae--immunology<br/>Th17 Cells--immunology<br/>Young Adult